Use the search parameters below to filter talks:

Calendar
Calendar

2010 - TTS International Congress (Vancouver)

Organ Donation and Allocation I
16 August 2010  /  10:30 - 12:00

Tools to compare organ procurement process

Presenter: Rosa Deulofeu, Barcelone, Spain

- Tools to compare organ procurement process

Presenter: Rosa Deulofeu, Barcelone, Spain

Induction Immunosuppression
16 August 2010  /  10:30 - 12:00

Final 36 Month Results Of A Multicenter, Randomized Trial Comparing Three Induction Agents (Alemtuzumab, Thymoglobulin and Basiliximab) With Tacrolimus, Mycophenolate Mofetil and a Rapid Steroid Withdrawal in Renal Transplantation

Presenter: E Steve Woodle, cincinnati, United States

- Final 36 Month Results Of A Multicenter, Randomized Trial Comparing Three Induction Agents (Alemtuzumab, Thymoglobulin and Basiliximab) With Tacrolimus, Mycophenolate Mofetil and a Rapid Steroid Withdrawal in Renal Transplantation

Presenter: E Steve Woodle, cincinnati, United States

Short- and long term kidney graft survival: the impact of intra-operative high-dose ATG-Fresenius induction and identification of important predictors

Presenter: Juergen Kaden, Berlin, Germany

- Short- and long term kidney graft survival: the impact of intra-operative high-dose ATG-Fresenius induction and identification of important predictors

Presenter: Juergen Kaden, Berlin, Germany

One year follow up efficacy and safety of induction therapy comparison of anti-interleukin-2 receptor antibodies and thymoglobulin

Presenter: Li Li, Stanford, United States

- One year follow up efficacy and safety of induction therapy comparison of anti-interleukin-2 receptor antibodies and thymoglobulin

Presenter: Li Li, Stanford, United States

Interleukin-2 receptor antagonists versus ATG for kidney transplant recipients; an updated Cochrane systematic review.

Presenter: Angela Webster, sydney, Australia

- Interleukin-2 receptor antagonists versus ATG for kidney transplant recipients; an updated Cochrane systematic review.

Presenter: Angela Webster, sydney, Australia

Induction Immunosuppression in the Elderly Kidney Transplant Recipient: An analysis of OPTN/UNOS data informing a risk stratified approach

Presenter: Jagbir Gill, Vancovouver, Canada

- Induction Immunosuppression in the Elderly Kidney Transplant Recipient: An analysis of OPTN/UNOS data informing a risk stratified approach

Presenter: Jagbir Gill, Vancovouver, Canada

To Wean or Not to Wean Tacrolimus Monotherapy After Alemtuzumab Pretreatment in Living Donor Kidney Transplant Recipients: A Comparative Study.

Presenter: Henkie Tan, ,

- To Wean or Not to Wean Tacrolimus Monotherapy After Alemtuzumab Pretreatment in Living Donor Kidney Transplant Recipients: A Comparative Study.

Presenter: Henkie Tan, ,

Impact of IL2-RA Induction Therapy in the Prevention of Acute Rejection with TAC/MMF-Based Immunosuppression

Presenter: Jane Gralla, Aurora, United States

- Impact of IL2-RA Induction Therapy in the Prevention of Acute Rejection with TAC/MMF-Based Immunosuppression

Presenter: Jane Gralla, Aurora, United States

Kidney transplantation with campath 1H and infliximab induction followed by either tacrolimus or sirolimus monotherapy: 12-months follow-up

Presenter: Ondrej Viklicky, Prague, Czech Republic

- Kidney transplantation with campath 1H and infliximab induction followed by either tacrolimus or sirolimus monotherapy: 12-months follow-up

Presenter: Ondrej Viklicky, Prague, Czech Republic

CMV Infection
16 August 2010  /  10:30 - 12:00

Development of primary CMV-specific T-cell responses in D+/R- transplant recipients during valganciclovir prophylaxis

Presenter: Corinna La Rosa, DUARTE, United States

- Development of primary CMV-specific T-cell responses in D+/R- transplant recipients during valganciclovir prophylaxis

Presenter: Corinna La Rosa, DUARTE, United States

Primary CMV Infections Are Common in Kidney Transplant Recipients after 6 Months Valganciclovir Prophylaxis

Presenter: Ilkka Helanterä, Helsinki, Finland

- Primary CMV Infections Are Common in Kidney Transplant Recipients after 6 Months Valganciclovir Prophylaxis

Presenter: Ilkka Helanterä, Helsinki, Finland

The IMPACT Study: Valganciclovir Pharmacokinetic Parameters Do Not Change When Extending Prophylaxis from 100 to 200 Days.

Presenter: Carla Washington, South San Francisco, United States

- The IMPACT Study: Valganciclovir Pharmacokinetic Parameters Do Not Change When Extending Prophylaxis from 100 to 200 Days.

Presenter: Carla Washington, South San Francisco, United States

In vivo viral microRNA profiling in a large cohort of transplant patients with CMV disease

Presenter: Luiz Lisboa, Edmonton, Canada

- In vivo viral microRNA profiling in a large cohort of transplant patients with CMV disease

Presenter: Luiz Lisboa, Edmonton, Canada

The IMPACT STUDY: Extending Valganciclovir Prophylaxis in Kidney Transplant High Risk (D+/R-) Recipients is Associated with Long-term Benefits.

Presenter: Atul Humar, Edmonton, Canada

- The IMPACT STUDY: Extending Valganciclovir Prophylaxis in Kidney Transplant High Risk (D+/R-) Recipients is Associated with Long-term Benefits.

Presenter: Atul Humar, Edmonton, Canada

Monitoring with or without Pre-emptive Therapy versus Prophylaxis for Cytomegalovirus (CMV) in Renal Transplant Patients

Presenter: Jacob Akoh, Plymouth,

- Monitoring with or without Pre-emptive Therapy versus Prophylaxis for Cytomegalovirus (CMV) in Renal Transplant Patients

Presenter: Jacob Akoh, Plymouth,

Association of Cytomegalovirus (CMV) Infection and Disease with Death and with Graft Loss or Death after Liver Transplant in High Risk Recipients

Presenter: Wendelyn Bosch, Jacksonville, United States

- Association of Cytomegalovirus (CMV) Infection and Disease with Death and with Graft Loss or Death after Liver Transplant in High Risk Recipients

Presenter: Wendelyn Bosch, Jacksonville, United States

The IMPACT study: 100-day vs 200-day prophylaxis with valganciclovir (Valcyte®) to reduce CMV disease post-transplant is cost-effective within US health care setting

Presenter: Alan Jardine, Glasgow,

- The IMPACT study: 100-day vs 200-day prophylaxis with valganciclovir (Valcyte®) to reduce CMV disease post-transplant is cost-effective within US health care setting

Presenter: Alan Jardine, Glasgow,

Immunosuppression for Liver Transplantation
16 August 2010  /  10:30 - 12:00

Donor specific antibodies found in nearly all patients who chronically rejected their liver transplant.

Presenter: Jacqueline O'Leary, Dallas, United States

- Donor specific antibodies found in nearly all patients who chronically rejected their liver transplant.

Presenter: Jacqueline O'Leary, Dallas, United States

No immunologic graft failure in consecutive 17 cases of ABO-incompatible living donor liver transplantation under rituximab prophylaxis

Presenter: Gi-Won Song, Seoul, Korea

- No immunologic graft failure in consecutive 17 cases of ABO-incompatible living donor liver transplantation under rituximab prophylaxis

Presenter: Gi-Won Song, Seoul, Korea

Predicting "operational tolerance" after liver transplantation

Presenter: Tommaso Maria Manzia, Rome, Italy

- Predicting "operational tolerance" after liver transplantation

Presenter: Tommaso Maria Manzia, Rome, Italy